4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 25c

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q2 EPS of ($0.98), $0.25 worse than the analyst estimate of ($0.73).

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.

You May Also Be Interested In

• Subaru, other Japan suppliers to team on delivery as Boeing raises output - Nikkei
• Morgan Stanley Downgrades Ultragenyx Pharma (RARE) to Equalweight
• Victoria’s Secret shares slump 16% on weak Q3 operating income outlook